Chapter 18. Recent advances in the chemotherapy of HIV

This publication has 39 references indexed in Scilit:

• HIV-1 integrase and RNase H activities as therapeutic targets
  Emerging Therapeutic Targets, 2002
• The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults
  AIDS Research and Human Retroviruses, 2002
• Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase
  Phytotherapy Research, 2002
• Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent
  Antimicrobial Agents and Chemotherapy, 2002
• Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression
  Clinical Infectious Diseases, 2002
• DPC-083
  Drugs of the Future, 2002
• DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants
  Antimicrobial Agents and Chemotherapy, 2001
• Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex
  Structure, 2001
• The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is affected by the thumb subdomain of the small protein subunits
  Journal of Molecular Biology, 2001
• AIDS — The First 20 Years
  New England Journal of Medicine, 2001